A Phase I Dose-Escalation Study of PHA-793887 Administered as a 1-hour IV Infusion on Days 1, 8 and 15 in a 4-Week Cycle in Patients With Advanced/Metastatic Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs PHA 793887 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 09 Dec 2009 Last checked against ClinicalTrials.gov record.
- 22 Oct 2009 New trial record